There is increasing evidence that not only the elevation of systolic and diastolic blood pressure (BP) but also the increase in BP variability (or fluctuation) are associated with hypertensive organ damages and the morbidity and mortality of cerebrovascular and cardiovascular events. However, the molecular mechanism whereby the increase in BP variability aggravates hypertensive organ damages remains unknown. Thus, we created a rat chronic model of a combination of hypertension and large BP variability by performing bilateral sino-aortic denervation in spontaneously hypertensive rat. A series of our studies using this model revealed that large BP variability induces chronic myocardial inflammation by activating local angiotensin II and mineralocorticoid receptor systems and thereby aggravates cardiac hypertrophy and myocardial fibrosis, leading to systolic dysfunction, in hypertensive hearts. In addition, large BP variability induces the aggravation of arteriolosclerotic changes and ischemic cortical fibrosis in hypertensive kidney via local angiotensin II system.
Keywords: Angiotensin II, cardiac hypertrophy, fibrosis, inflammation, mineralocorticoid receptor, statins.
Hypertensive Left Ventricular Hypertrophy Regression: Does It Matter?
Current Hypertension Reviews Mutations and Common Polymorphisms in ADAMTS13 and vWF Genes Responsible for Increasing Risk of Thrombosis
Cardiovascular & Hematological Disorders-Drug Targets The Protective Role of Crocus Sativus L. (Saffron) Against Ischemia- Reperfusion Injury, Hyperlipidemia and Atherosclerosis: Nature Opposing Cardiovascular Diseases
Current Cardiology Reviews Impact of Diabetes on Cardiac and Vascular Disease: Role of Calcium Signaling
Current Medicinal Chemistry Epidemiology and Natural History of Patients with NAFLD
Current Pharmaceutical Design ACE Inhibition, p300, Serum Nitrite and Lipid Peroxidation in Newly Diagnosed Hypertensives
Vascular Disease Prevention Oxidative Stress and Endothelial Dysfunction in Cardiovascular Disease: Mitochondria-Targeted Therapeutics
Current Medicinal Chemistry Pharmaceutical Care: Past, Present and Future
Current Pharmaceutical Design An Overview of Cardenolides in Digitalis - More Than a Cardiotonic Compound
Current Pharmaceutical Design Resistant Hypertension in the Elderly-Second Line Treatments: Aldosterone Antagonists, Central Alpha-Agonist Agents, Alpha-Adrenergic Receptor Blockers, Direct Vasodilators, and Exogenous Nitric Oxide Donors
Cardiovascular & Hematological Agents in Medicinal Chemistry Role of the heme oxygenase-adiponectin-atrial natriuretic peptide axis in renal function
Current Pharmaceutical Design Role of Redox Homeostasis and Inflammation in the Pathogenesis of Pulmonary Arterial Hypertension
Current Medicinal Chemistry Molecular Basis of Adrenomedullin 1 Receptor Function and Its Roles in the Cardiovascular System
Current Hypertension Reviews Role of NADPH Oxidase in Hypertension and Diabetic Nephropathy
Current Hypertension Reviews Betaxolol Hydrochloride Loaded Chitosan Nanoparticles for Ocular Delivery and their Anti-glaucoma Efficacy
Current Drug Delivery Effects of an Outpatient Service Rehabilitation Programme in Patients Affected by Pulmonary Arterial Hypertension: An Observational Study
Cardiovascular & Hematological Disorders-Drug Targets Hypertension in Pregnancy: Clinical Manifestations and Treatment
Current Hypertension Reviews Cardiotonic Steroids in Adaptation to Dietary Salt Intake
Current Clinical Pharmacology Recent Patents on Rho Signaling Pathway as Therapeutic Target for Cardiovascular Diseases
Recent Patents on Cardiovascular Drug Discovery (Discontinued) Sleep Duration as a Risk Factor for Cardiovascular Disease- a Review of the Recent Literature
Current Cardiology Reviews